Skip to main content

Table 1 Clinical characteristics of hepatocellular carcinoma in train and validation cohort

From: Development of a novel immune-related lncRNA prognostic signature for patients with hepatocellular carcinoma

Clinicopathological variables

Entire cohort

Train cohort

Validation cohort

P-value

(N = 342)

(N = 230)

(N = 112)

Status, N (%)

   

0.504

 Alive

219 (64.0)

144 (62.6)

75 (67.0)

 

 Dead

123 (36.0)

86 (37.4)

37 (33.0)

 

Age (years), N (%)

   

0.768

  ≤ 65

216 (63.2)

147 (63.9)

69 (61.6)

 

 >65

126 (36.8)

83 (36.1)

43 (38.4)

 

Gender, N (%)

   

0.961

 Female

109 (31.9)

74 (32.2)

35 (31.2)

 

 Male

233 (68.1)

156 (67.8)

77 (68.8)

 

T-stage, N (%)

   

0.412

 T1

168 (49.1)

108 (47.0)

60 (53.6)

 

 T2

84 (24.6)

55 (23.9)

29 (25.9)

 

 T3

74 (21.6)

55 (23.9)

19 (17.0)

 

 T4

13 (3.8)

9 (3.9)

4 (3.6)

 

 Unknow

3 (0.9)

3 (1.3)

0 (0.0)

 

N-stage, N (%)

   

0.411

 N0

239 (69.9)

166 (72.2)

73 (65.2)

 

 N1

3 (0.9)

2 (0.9)

1 (0.9)

 

 Unknow

100 (29.2)

62 (27.0)

38 (33.9)

 

M-stage, N (%)

   

0.453

 M0

244 (71.3)

165 (71.7)

79 (70.5)

 

 M1

3 (0.9)

1 (0.4)

2 (1.8)

 

 Unknow

95 (27.8)

64 (27.8)

31 (27.7)

 

AJCC stage, N (%)

   

0.213

 Stage I

161 (47.1)

105 (45.7)

56 (50.0)

 

 Stage II

77 (22.5)

51 (22.2)

26 (23.2)

 

 Stage III

80 (23.4)

61 (26.5)

19 (17.0)

 

 Stage IV

3 (0.9)

1 (0.4)

2 (1.8)

 

 Unknow

21 (6.1)

12 (5.2)

9 (8.0)

 

Grade, N (%)

   

0.56

 G1

53 (15.5)

34 (14.8)

19 (16.9)

 

 G2

161 (47.1)

104 (45.2)

57 (50.9)

 

 G3

111 (32.5)

78 (33.9)

33 (29.5)

 

 G4

12 (3.5)

10 (4.3)

2 (1.8)

 

 Unknow

5 (1.5)

4 (1.7)

1 (0.9)

Â